For the treatment of chronic diffuse liver diseases

 

(57) Abstract:

The invention relates to medicine, in particular to pharmacology and gastroenterology. Goal is to improve therapeutic efficacy in the treatment of chronic diffuse liver diseases. For this purpose it is proposed to use Touchard, known first as the drug having anti-hypertensive activity. 5 table.

The invention relates to medicine, in particular therapy and pharmacology, and relates to means for the treatment of chronic diffuse liver diseases.

Known means for the treatment of this pathology: hormones, drugs, improves metabolic processes in the liver. However, in some cases, these tools are ineffective, have contraindications to their use, can be assigned when there is absolutely certain clinical situations, and do not have a positive effect on the liver.

There is a method of treatment of chronic diffuse liver disease with the use of hepatoprotectors, in particular legalon (2-3 capsules 3 times a day), adopted for the prototype. It is established that the drug is contraindicated in patients with hypersensitivity to the Vita is the influence of legalon is not changed by the liver and to achieve a therapeutic effect requires long-term medication.

The purpose of the invention is a means for the treatment of chronic diffuse liver diseases, which can be used at any stage of the pathological process, including the ineffectiveness of the previous therapy (hormonal therapy, Essentiale) that have a positive therapeutic effect in the short term and positive impact on the liver.

This goal is achieved by the use of the drug toward synthesized in the NGO Cursham" and have undergone clinical testing. For the treatment of chronic diffuse liver diseases designate toward 0.5 g 2 times a day.

Use lower dose specified in the clinical studies did not reveal her any significant impact on the liver.

P R I m e R 1. Is given as an illustration of the ineffectiveness of doses toward less than 1 g/day.

Patient T. A. A., 18 years. Diagnosis: chronic persistent hepatitis. For correcting liver function assigned Touchard at a dose of 0.5 g/day. After administration of the drug is estimated changes in hepatic hemodynamics and the activity of liver-specific enzymes. The data obtained are presented in table. 1.

As follows from the prii enzymes.

The use of doses over 1 g/day. once taking the drug and long-term therapy may lead to undesirable metabolic and/or hemodynamic effects on the liver and worsening of the clinical course of the disease.

P R I m m e R 2. Is given as an illustration of the appearance of side effects Touchard in a patient with chronic persistent hepatitis with a daily dose of Preparata more than 1,

Patient L. S. C., 55 years, N history 2784. Diagnosis: chronic persistent hepatitis. With the purpose of treatment the patient is assigned toward in the dose of 1.5 g/day. After taking the drug investigated the blood flow of the liver and the activity of liver-specific enzymes. The data obtained are presented in table. 2.

As follows from the presented data, the patient admission Touchard in the dose of 1.5 g/day. there is a decrease in blood flow to the liver and increase the activity of enzymes, which indicates an increase of cytolytic syndrome.

Clinical efficacy toward in patients with chronic diffuse liver diseases confirm the following examples.

P R I m e R 3. Ill, C. M., 48, N history 421. Diagnosis: chronic persistent g is hormones (prednisolone) is ineffective. Changes of hemodynamics and liver function are presented in table. 3.

From the presented data clearly a significant improvement of hepatic blood flow and reduced cytolytic and inflammatory syndrome liver.

P R I m e R 4. Patient N. E. In., 18, outpatient map N 13. Diagnosis: chronic active hepatitis. From the anamnesis: suffering with CPH about 8 years. This exacerbation of about 3 months. Prior hormonal therapy (prednisolone 40 mg/day. ) to the clinical laboratory improvement has not led: there is a high activity enzymes and a decrease in hepatic blood flow. After a course of therapy cougardom dose of 1 g/day. duration 21 days showed significant clinical improvement. Changing hemodynamic and Entomologicheskoe indicators are presented in table. 4.

P R I m e R 5. Patient H. A. A., 55, outpatient map N 47. Diagnosis: biliary cirrhosis. Prior corticosteroid therapy ineffective (significant reduction in hepatic blood flow). Patients received 2-week course of therapy with cougardom dose of 1 g/day. The observed decrease in the pain in the right hypochondrium and size of the liver. The blood flow of the liver increased from 351 ml/min/100 l of the experimental examples illustrate the possibility of using Touchard in the treatment of chronic diffuse liver diseases. The positive effect of Touchard in patients with chronic diffuse liver disease is confirmed by its use in 27 patients with pathology of the hepato-biliary system.

The positive effect of Touchard in patients with chronic hepatitis may be confirmed by the data shown in the table. 5.

The data presented indicate a significant increase in the blood flow of the liver, and reduced cytolytic syndrome under the action of Touchard.

Application toward as a means for the treatment of chronic diffuse liver diseases.

 

Same patents:
Bronchodilatory // 2024255
The invention relates to medicine, in particular to pulmonology and pharmacology

The invention relates to medicine, namely to addiction

The invention relates to medicine

The invention relates to the field of medicine
The invention relates to the field of medicine

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to compounds designated for applying in photochemotherapy or diagnosis and indicated compounds represent 5-aminolevulinic acid aryl-substituted esters, their derivatives or pharmaceutically acceptable salts. In particular, invention provides preparing compounds of the general formula (I): R

22
N-CH2COCH2CH2CO-OR1 wherein R1 represents aryl-substituted C1-alkyl group, preferably C1-alkyl group substituted with non-heteroaromatic aryl wherein indicated group aryl is substituted group, and especially preferable this radical is substituted with one or more alkyl groups (for examples, (C1-C2)-alkyl), alkoxy- (for example, methoxy-) groups, fluorine, chlorine atoms, nitro- or trifluoromethyl groups; R2 being each of that can be similar or different represents hydrogen atom or alkoxycarbonyloxy-; indicated alkyl group is broken optionally with one or more groups: -O-, -NR3-, -S- or -PR3- wherein R3 represents hydrogen atom or (C1-C6)-alkyl group, and their salts for applying in diagnosis and photochemotherapy of injures and disorders of internal and external surfaces of body, and products and sets for realization of this invention also.

EFFECT: valuable medicinal properties of compounds.

18 cl, 17 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out analysis of clinical manifestations in patients having satisfaction deficiency syndrome. Clinical manifestations like obsessive compulsive disorders occurring, physical training exercises acting upon visceral organs as a result of abdominal wall muscle and inferior and superior small pelvis diaphragm muscle contraction. Clinical manifestations like irritation and aggressiveness being observed, physical training exercises like slow diaphragm-type breathing with deep muscle relaxation or alternating hyperventilation and deep diaphragm-type breathing are to be done. Clinical manifestations like hyperactivity taking place, physical dynamic exercises causing activating action are done in combination with slow deep breathing. Clinical manifestations like emotional disorders being observed, physical training exercises causing sedative action are applied. The exercises are based on alternating muscle and tendon extension and following relaxation. Dietetic low hydrocarbon content nutrition is additionally applied with one of the following diets: low hydrocarbon content diet having animal proteins and saturated with fat, or vegetarian diet having mainly vegetable proteins, moderate hydrocarbon content and large amount of vegetable fibers, or ketogenic diet being protein-and-fat diet containing large amount of fat with fatty acids like triglycerides of chain having not more than 12 carbomers.

EFFECT: enhanced effectiveness of prophylaxis and correction procedures.

11 cl

FIELD: cosmetic industry.

SUBSTANCE: the present innovation deals with preparations to fix, strengthen, restructure, restore or stabilize keratin fibers, especially damaged fibers. For this purpose one should apply creatine, creatinine and/or their salts to provide improves glare, volume or combing capacity of one's hair, as well. Earlier these preparations had been known as hair moisturizers.

EFFECT: higher efficiency of application.

12 cl, 9 ex

FIELD: medicine.

SUBSTANCE: preparation is a crushed and UV-radiation activated β-(3-indolyl)-α-aminocapronic acid obtained by treating dry initial preparation (native aminocapronic acid) crushed to 1-5 mcm large particles with UV-radiation during 12-18 h to the moment the substance decomposition starts. Method involves crushing dry substance of β-(3-indolyl)-α-aminocapronic acid by means of vibration mill with 1500-3000 oscillations per min to 1-5 mcm large particles, activating the crushed product by exposing it to UV-radiation of 250-280 nm wavelength during 12-18 h to the moment the initial substance decomposition starts. The moment is determined by 3-5% large initial mass loss.

EFFECT: enhanced effectiveness of the preparation with no adverse side effects.

6 cl, 3 tbl

FIELD: medicine, dermatology.

SUBSTANCE: one should apply an applicator onto affected parts of skin that contains 5-aminolevulinic acid at concentration of 5-20%. After keeping and removing the applicator it is necessary to irradiate with light at wave length being 630 ± 10 nm and energy density of 10-1200 J/sq. cm. Control should be carried out due to evaluating the concentration of photosensitizer at affected parts of skin due to fixing fluorescence ranges at all basic stages of photodynamic therapy. The method enables to adjust skin relief and achieve scars' whitening and their regression.

EFFECT: higher efficiency of therapy and control.

6 cl, 2 dwg, 3 ex

FIELD: medicine, gynecology, anesthesiology.

SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.

EFFECT: improved assistance method.

7 tbl, 4 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates, in particular, to a composition for interaction of ligands wherein the composition comprises a noncovalent associate of multiple separate conjugates being each of that comprises a head group and a tail group wherein tail groups of conjugates form hydrophobic aggregate. Conjugates are mobile within the associate and in the presence of ligand at least two head groups are places by a method corresponding to the epitope formation that is able to interact with ligand stronger as compared with each separate head group. Invention provides applying conjugates in combinatory approach for detecting effective combinations to induce the desirable interaction in binding in receptor-specific treatment of patients.

EFFECT: valuable properties of epitopes.

31 cl, 2 dwg, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: physiologically acceptable sodium salt is dissolved in purified apyrogenic water in the concentration 5-10 g/100 ml and colloidal substance of polymeric nature is added at temperature of solution 40-70C at stirring up to disappearance of polymer solid phase from the surface solution. Solution is stirred for 30-60 min and then subjected for high-temperature treatment at 90-100°C for 15-30 min and successive filtration through micro- and sterilizing filters of pores diameters 0.8 and/or 0.45 and then 0.22 mcm, respectively, and in gradual increasing the pressure value from 0.5 to 3.0 atm and final packaging. Invention provides preparing microimpurity-free hypertonic colloidal solution that is stable in storage and effective in using. Invention can be used in methods for preparing preparations used in reanimatology, intensive therapy and in emergency medicine.

EFFECT: improved preparing method, valuable medicinal properties of preparation.

8 cl, 3 ex

Up!